EQT to acquire the TachoSil® biosurgery business from Corza Medical

EQT has announced its agreement to acquire Corza Biosurgery, a prominent player in the biosurgery sector known for its flagship product, TachoSil, a dual-action hemostat and sealant patch. The transaction, which is valued at an undisclosed amount, is expected to close in the fourth quarter of 2026. This acquisition marks a strategic move for EQT, aimed at bolstering its healthcare portfolio and enhancing the growth trajectory of Corza Biosurgery.

Corza Biosurgery, which operates out of Linz, Austria, has established itself as a leader in complex surgical biologics over its 20-plus years in the industry. TachoSil is utilized by surgeons in more than 50 countries and is recognized for its efficacy in controlling bleeding and sealing tissues during various surgical procedures, including cardiovascular and neuro surgeries. The product's strong clinical backing, with over 540 published clinical trials, underscores its reputation among healthcare providers and surgeons, making it a critical tool in improving surgical outcomes.

EQT's acquisition strategy includes a commitment to support the management team of Corza Biosurgery, led by President Thierry Leclercq, in the next phase of growth. The investment will focus on commercial acceleration, geographic expansion, and innovation to enhance TachoSil's market presence. EQT aims to leverage its healthcare expertise and global network to drive growth in the U.S. market and other underpenetrated regions, as well as explore opportunities for complementary acquisitions to build a broader biosurgery platform.

The healthcare sector is experiencing increasing demand for innovative solutions that enhance patient outcomes, particularly as surgical procedures become more complex. With an aging population and a rise in chronic diseases, the need for effective surgical interventions is more critical than ever. TachoSil's ability to facilitate rapid hemostasis and effective tissue sealing positions it well to meet these demands, potentially leading to shorter recovery times and improved surgical efficiencies.

As EQT moves forward with this acquisition, the broader market implications could be significant. The investment in Corza Biosurgery reflects a growing trend among private equity firms to capitalize on the increasing need for advanced medical technologies and solutions in the healthcare sector. The focus on innovation and expansion within Corza Biosurgery may set a precedent for similar transactions, as investors seek to support companies that are poised to make substantial impacts on patient care and surgical practices globally.